Photodynamic Therapies May Give Better Treatment for Mesothelioma in Comparison to Radiation Therapy
Cancer doctors decide what course of treatment to go with with each patient. The options are endless. There are no regular treatment regimen for malignant mesothelioma cancer sufferers. This is because of the relative rareness of the disease, the high mortality rate and low treatment success rate, and the few scientific studies to provide meaningful statistics.
While prospects for patients with mesothelioma have been bleak, doctors have been making progress. Treatments for cancer are traditionally surgery (taking out the tumor and surrounding tissue), chemotherapy (poisoning cancerous cells) and radiation (killing cancer cells with radiation) Each one of these methods have problems. Mesothelioma patients treated with traditional radiation therapy have not responded well to it. Researchers are looking for ways of aiming radiation directly at the tumor in hopes that this will result in less damage to healthy tissue.
The mesothelial tissue around the tumor is removed by surgery. The surgery is difficult and challenging, with unknown effects or benefits to patients. The usual chemotherapy cocktails effective on other cancers are not effective on mesothelioma, and different mixtures of these drugs have not been successful. Similar to radiation, focus in research is focusing on treating the physical location of the tumor with emphasis on the pleural cavity.
The death rate for mesothelioma is so high that many of even the most sophisticated techniques in cancer treatment are tried out on patients. These include biologic therapy such as the agent interleukin 2 and anti-angiogenesis drugs such as thalidomide. Pemetrexed (Alimta) is a new drug that has shown results in extending life.
Oncologists consider the stage of mesothelioma, the location of the tumor, the patient’s age and state of health at the time. Two exotic ways of attacking mesothelioma are gene therapy and photodynamic therapy. Patients afflicted with mesothelioma are benefitting in these clinical trials.
